Three medicines are currently available in Australia that can help slow or stop the progression of SMA. While there is no cure for SMA, treatment focuses on managing symptoms and improving quality of life.
SMA Australia does not recommend any specific treatment for people living with SMA.
Your healthcare team will provide detailed information about available treatments and develop a personalised management plan tailored to you or your child's needs.
SMA Australia will continue to advocate for the latest treatment options approved overseas to be made available to Australians living with SMA and update our community as this access is granted. New treatments for SMA are being researched, developed and evaluated through processes, such as clinical trials.
Evrysdi is a liquid medicine that is taken by mouth or a feeding tube at home, once daily after a meal and at approximately the same time each day. Can be taken with or without food.
Spinraza is a medicine administered by a doctor who is experienced in giving injections into the lower back. This injection, also known as a lumbar puncture or spinal tap, involves inserting a needle in the space around the spinal cord (intrathecal space). You or your child may be given a medicine to help induce relaxation or sleep (sedation) before being given Spinraza, and an ultrasound or other imaging equipment may be used to guide the insertion of the needle.
Zolgensma is a treatment given by a doctor or nurse experienced in treating SMA. It is injected into a vein in your child’s arm or leg, in a process called intravenous (IV) infusion. This treatment slowly delivers the medicine into the bloodstream and only needs to be given once.
Evrysdi helps the body’s Survival of Motor Neuron 2 (SMN2) gene to make more Survival of Motor Neuron (SMN) protein, and taking the medicine consistently helps to maintain these higher SMN levels throughout the body. This increased amount of SMN protein available to motor neurons helps more of them to stay alive, which can lead to improved muscle strength and function in people with SMA. Given the medicine stops muscle weakness and wasting from getting worse, it is important that treatment is started as early as possible.
Lorem ipsum dolor sit amet consectetur. Sed enim aenean nisi consectetur laoreet. Tellus iaculis lectus semper lorem posuere egestas mollis pretium porta. Quis sed mauris lorem diam. Sit et pellentesque venenatis porta non curabitur id.
Your neurologist will advise the best treatment option for you or your child with SMA.
Evrysdi is available on the Pharmaceutical Benefits Scheme (PBS) for people of all ages with SMA types 1–3 who have SMA symptoms, or people who do not yet have symptoms but do have one, two or three copies of the SMN2 gene.
As Evrysdi is a specialised medicine that is unlikely to be carried in stock by regular local pharmacies, a home delivery service is available to all patients. By enrolling in the program, the medication will be delivered directly to you, at a convenient time for you. Speak to your healthcare professional for more information and to enrol.
Spinraza helps the body’s SMN2 gene to produce more SMN protein. Once SMN is increased, regular doses of Spinraza are needed to keep these levels up. When motor neurons have more SMN protein available, less of them will die, which can help people with SMA to maintain and improve their muscle strength and function. Given the treatment stops muscle weakness and wasting from getting worse, it is important to start treatment as early as possible.
Your neurologist will advise the best treatment option for you or your child with SMA.
Spinraza is available on the Pharmaceutical Benefits Scheme (PBS) for people of all ages with SMA types 1-3 who have SMA symptoms, or people who do not yet have symptoms but do have one, two or three copies of the SMN2 gene.
Spinraza treatment begins with four injections over a period of two months, known as loading doses. After this, you or your child will require one dose every four months to maintain its effects. Unless agreed otherwise by the neurologist, treatment will continue on an ongoing basis.
The CMI provides important information about using Spinraza.
Zolgensma delivers a new, working gene into the body which mimics SMN1, the gene that is reduced, missing or faulty in people with SMA. The gene is delivered to the motor neurons by a viral vector called AAV9, which is a virus that is not harmful or known to make people sick but instead has been modified to be used for transporting. To make the vector, the DNA of the virus is removed so that the new SMN gene can be put inside.
Once the gene reaches the motor neuron, it helps the body produce enough SMN protein. The increased amount of SMN protein available to motor neurons can help slow or stop the muscle weakness and wasting in people with SMA from getting worse. Given this, it is important treatment is started as early as possible.
Your neurologist will advise the best treatment option for your child with SMA.
Zolgensma is available on the Pharmaceutical Benefits Scheme (PBS) for children under 9 months of age, symptomatic and diagnosed with SMA Type 1, or children who do not yet have symptoms but do have one, two or three copies of the SMN2 gene.
If your child has developed an immunity to AAV9, which is naturally found in the environment, they will not benefit from Zolgensma treatment. As such, all children being considered for treatment with Zolgensma will be tested for the AAV9 antibody, and if they show a response, they will be ineligible for this treatment. As AAV9 antibodies decline over time, children under 9 months age can be retested to check eligibility.
Zolgensma is a gene therapy that has been engineered to contain the SMN1 gene. Treatments like Zolgensma can quickly increase the levels of available SMA protein in the body after administration. Some irreversible damage may have already occurred to the motor neurons that have been without enough SMA protein for some time. This may happen even before a baby is born.
The CMI provides important information about using Zolgensma.
The CMI provides important information about using Evrysdi.
Physical therapies are an important part of SMA treatment. They can support muscle health and help people navigate the everyday challenges they face when living with SMA. It is especially important for children with SMA, as starting treatment early and following the management plan closely can help them reach their full potential.
Physical therapies can include:
Speak to your healthcare professional about which physical therapies might be right for you or your child.
If you have forgotten your password, you can easily reset it by following these steps:
Make sure to choose a strong password that you haven't used before.
If you need assistance, our support team is here to help. You can reach us through the following methods:
We aim to respond to all inquiries within 24 hours.
To keep your information current, follow these steps to update your profile:
Ensure that your email and phone number are accurate for account recovery.
If you wish to delete your account, please be aware that this action is permanent. To proceed:
If you have any concerns, please contact support before deleting your account.
To change the email address associated with your account, follow these steps:
Make sure to check your spam folder if you do not see the confirmation email.
SMA is caused by a problem with a gene called Survival of Motor Neuron 1 (SMN1). Everyone has two copies of the SMN1 gene, however, some people might have one working copy and one ‘faulty’ copy of the gene. These people are called ‘carriers’. Carriers do not have SMA, because of their one working copy of the gene.
Approximately 1 in 50 people carry one faulty copy of the SMN1 gene.
If you and your partner are both carriers of a faulty SMN1 gene, there is a one in four (25%) chance you will have a child with SMA.
Genetic carrier screening for SMA is available in Australia. Speak to your doctor, obstetrician or genetic counsellor for more information.
From 1 November 2023, genetic carrier screening for SMA, Cystic Fibrosis and Fragile X syndrome was made freely available through Medicare to Australians who are pregnant or planning a pregnancy and their reproductive partner, helping them to make more informed reproductive choices. For those people who do not meet these Medicare criteria, testing is available at a cost. Speak to your testing provider for further information.
If genetic carrier screening shows you and your partner are at risk of passing SMA onto your child, rest assured this does not mean you are not able to have a baby – it just means you need to do some extra planning. Your healthcare team will guide you through options for current and future pregnancies, including family planning options such as in vitro fertilisation (IVF).
If you have recently been made aware that SMA runs in your family, or have noticed symptoms that might indicate SMA in you or your child, speak to your doctor for more information about testing. Symptoms to keep an eye out for include:
If SMA is suspected, a blood test will be requested, which will look for the presence or absence of the SMN1 gene. If the SMN1 gene is absent, SMA can be diagnosed.
If the gene is present, other diagnostic tests will take place to rule out rare forms of SMA caused by changes to different genes, and other neuromuscular conditions. In two to five per cent of patients with SMA, the SMN1 gene is not missing, just inactive. Testing for this is more complicated and may take some time.
The healthcare professional simply needs to take a blood sample. Some discomfort may be felt as part of standard blood test procedures.
From 1 November 2023, genetic carrier screening for SMA, Cystic Fibrosis and Fragile X syndrome was made freely available through Medicare to Australians who are pregnant or planning a pregnancy and their reproductive partner, helping them to make more informed reproductive choices. For those people who do not meet these Medicare criteria, testing is available at a cost. Speak to your testing provider for further information.
Results are usually reported to your or your child’s doctor within two weeks of the laboratory receiving the blood sample.
If you or your child is diagnosed with SMA, your GP will refer you to a neurologist who will take you through next steps, including further information on living with the condition and the treatment options available.
If your child is diagnosed with SMA, they will have a certain type of the condition. Each type has a different impacts on the quality and length of life, with different treatment options available for each type of disease. Further information can be found at our Children (0-12) Living With SMA page.
If your child is diagnosed with SMA as a teenager, they may have some muscle wasting and movement limitations, and other symptoms such as scoliosis. You may need to make some accommodations to help them live a full life with SMA. More information can be found at our Teenagers (13-17) Living With SMA page.
Adult-onset SMA is often a mild form of the disease, with minor impacts on quality of life. More information can be found at our Adults (18+) Living With SMA page.
People living with SMA will be supported by a multidisciplinary healthcare team, which should include a GP and neurologist, and can include specialists such as physiotherapists and occupational therapists. There are also external support services available, such as SMA Australia’s peer to peer support programs. More information on external support services is available under 'Living with SMA'.
The impact of SMA on quality of life depends on the severity of symptoms. However, support is available to help everyone living with SMA to reach their full potential. The treatment landscape for the condition is also rapidly evolving.
There is currently no cure for SMA, however, treatments are available for eligible patients. More information can be found at our Treatments page.
There are a range of support services available to people living with SMA, their carers and families:
A multidisciplinary healthcare team will support you or your child to live well with SMA. This should includes a General Practitioner (GP) and a neurologist, and can also include specialists such as a respiratory physician, dietitian, orthopaedic surgeon, allied health therapist (physiotherapist, occupational therapist or speech therapist) and genetic counsellor.
Home modifications might be required to accommodate someone living with SMA, such as widened doorways to accommodate a wheelchair, or ramps to assist those with reduced movement. Speak to your occupational therapist for more information.
Most students with disabilities attend regular classes in mainstream schools. Some students may need adjustments in these environments, or to attend support classes with fewer students who require similar accommodations. Depending on your child's individual needs, you might also consider a specialist school (public or private). For some children, a combination of specialist and mainstream schooling works well. Homeschooling or distance education are also possibilities to explore.
SMA Australia brings together a community of people living with SMA and their loved ones, to support people living with the condition through initiatives like peer-to-peer counselling, educate the wider public about the condition, and advocate for access to the best care and latest treatments.
Newborn screening is a way to identify common conditions that can be treated if caught early, minimising the impacts on long-term health and survival. The NBS program is a free test offered to you a few days after your baby is born. If you agree to the testing, a midwife or nurse will prick your baby’s heel and collect a small sample of blood on a special filter paper card – a ‘bloodspot’ – which will be sent to a laboratory to test for conditions such as SMA.
Early diagnosis of conditions like SMA is important, because it means treatment can be started as early as possible and the impacts of SMA on your child can be reduced.
Collecting a bloodspot is safe and does not harm your baby – they may feel some brief discomfort, but holding or feeding them while the bloodspot is collected can help.
Results will be reported to your doctor a few days or weeks after the sample has been collected. Timing differs between States/Territories.
If your child is diagnosed with SMA, your GP will refer you to a neurologist who will take you through next steps, including further information on living with the condition and the treatment options available.
Whilst genetic carrier screening can test if you and your partner risk passing SMA on to your child, it cannot be used to diagnose your child with SMA. Prenatal screening provides you with a clearer understanding of your child’s SMA diagnosis and can help guide conversations with your healthcare team regarding continuing your pregnancy and considering treatment options for your child.
The types of SMA are based on the age at which symptoms first appeared and the effect of these symptoms on growth, development and quality of life. The different SMA types have varied impacts and different treatment options, and include:
* However, in Australia, recent innovations facilitating timely diagnosis and treatment of SMA have started to change the way these types of SMA can be defined.
There are also some rarer forms of SMA:
For many years, there were no medicines available for SMA. However, innovation over the past decade has transformed the SMA landscape as families now have access to treatments.
Three medicines are currently available in Australia that can help slow or stop the progression of SMA. These treatments may also improve muscle function and life expectancy, though their long-term effects are still being studied.
While there is no cure for SMA, treatment focuses on managing symptoms and improving quality of life. A multidisciplinary healthcare team will support you throughout your journey with SMA.
More information on treatments can be found at our Treatments page.
Your neurologist will develop a treatment plan that suits you or your child’s individual needs.
Since there is no cure for SMA, treatment to manage the condition will be ongoing, unless advised otherwise by your healthcare team. Some available medicines will only require one dose. Further information on treatment can be found at our Treatments page.
The Pharmaceutical Benefits Scheme (PBS) subsidises the three medicines that are currently available in Australia. Patients must be eligible for the PBS and meet the relevant restriction criteria.
The cost of other treatment options, such as physical therapy to help manage the condition, varies greatly.
Your healthcare team can provide you with advice on the cost of treatment, as well as information on options for assistance.
Physical therapies are an important part of SMA treatment. They can support muscle health and help people navigate the everyday challenges they face when living with SMA. It is especially important for children with SMA, as starting treatment early and following the treatment plan closely can help them reach their full potential.
Working with a multidisciplinary healthcare team is also important for managing SMA and may include specialists, such as a dietitian.
New treatments for SMA continue to be researched, developed, and evaluated through clinical trials. SMA Australia advocates for the latest overseas-approved treatment options to be made available to Australians living with SMA and will keep the community updated as access expands.
Clinical trials – research studies that assess the safety and effectiveness of new medical treatments, tests or procedures in people – may be available for you or your child. Your neurologist can advise on relevant trials, or you can explore current worldwide clinical trials at ClinicalTrials.gov and discuss potential options with your neurologist.
For a broader view of SMA drug development, the Cure SMA (US) website provides a detailed pipeline of medicines at various stages, from pre-clinical discovery to FDA approval and availability in the United States. You can explore the SMA Drug Pipeline here.
In Australia, the Therapeutic Goods Administration (TGA) oversees medicine approvals, ensuring treatments meet rigorous standards for safety, efficacy, and quality before becoming available to the public. While some medicines gain TGA approval soon after receiving FDA approval, others may face a longer process due to factors such as local clinical trials and additional data requirements – or may not receive TGA approval at all.
Once approved by the TGA, a treatment can be submitted to the Pharmaceutical Benefits Advisory Committee (PBAC) for evaluation. Medicines that receive a positive PBAC recommendation and are subsequently listed on the Pharmaceutical Benefits Scheme (PBS) become accessible for eligible patients in Australia.
This website is not intended to replace medical advice. Please speak to your healthcare professional for more information.
Join a powerful community of supporters who are helping tackle spinal muscular atrophy at its very core. Our community relies on us for support and best-practice resources to guide them in living well with SMA, as well as for resources to help raise disease awareness, educate others and advocate for people living with SMA in the wider Australian community.
